Trecator® (ethionamide tablets, USP) is used in the treatment of tuberculosis.
Trecator-SC (ethionamide) is primarily indicated for the treatment of active tuberculosis in patients with
resistant to isoniazid or rifampin, or when there is intolerance on the part of the patient to other drugs. Its use alone in the treatment of tuberculosis results in the rapid development of resistance. It is essential, therefore, to give a suitable companion drug or drugs, the choice being based on the results of susceptibility tests. If the susceptibility tests indicate that the patient's organism is resistant to one of the first-line antituberculosis drugs (i.e., isoniazid or rifampin) yet susceptible to ethionamide, ethionamide should be accompanied by at least one drug to which the
isolate is known to be susceptible.6 If the tuberculosis is resistant to both isoniazid and rifampin, yet susceptible to ethionamide, ethionamide should be accompanied by at least two other drugs to which the
isolate is known to be susceptible.6
Patient nonadherence to prescribed treatment can result in treatment failure and in the development of drug-resistant tuberculosis, which can be life-threatening and lead to other serious health risks. It is, therefore, essential that patients adhere to the drug regimen for the full duration of treatment. Directly observed therapy is recommended for all patients receiving treatment for tuberculosis. Patients in whom drug-resistant
organisms are isolated should be managed in consultation with an expert in the treatment of drug-resistant tuberculosis.
Media Articles Related to Trecator (Ethionamide)
Boosting the immune system with vitamin A may help in the fight against tuberculosis
Source: Cholesterol News From Medical News Today [2014.02.27]
Tuberculosis is a major global problem, affecting 2 billion people worldwide and causing an estimated 2 million deaths annually. Western countries are once again tackling the disease, with recent outbreaks in Los Angeles and London.
Tuberculosis Skin Test (PPD Skin Test)
Source: MedicineNet Immunizations Specialty [2014.01.30]
Title: Tuberculosis Skin Test (PPD Skin Test)
Category: Procedures and Tests
Created: 1/13/2004 12:00:00 AM
Last Editorial Review: 1/30/2014 12:00:00 AM
Promising class of antibiotics discovered for treatment of drug-resistant tuberculosis
Source: MRSA / Drug Resistance News From Medical News Today [2014.01.29]
St. Jude Children's Research Hospital scientists have discovered a promising new class of antibiotics that could aid efforts to overcome drug-resistance in tuberculosis (TB), a global killer. The drugs increased survival of mice infected with TB and were effective against drug-resistant strains of TB. St.
Source: MedicineNet Amyloidosis Specialty [2014.01.24]
Title: Tuberculosis (TB)
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 1/24/2014 2:28:22 AM
Early signs that patient's own bone-marrow stem cells could treat multi-drug resistant tuberculosis
Source: MRSA / Drug Resistance News From Medical News Today [2014.01.14]
Findings of a preliminary study published in The Lancet Respiratory Medicine suggest that a patient's own bone-marrow stromal (stem) cells could be used to treat multidrug-resistant (MDR) and extensively-drug (XDR) tuberculosis (TB)*. "Conventional treatment for MDR-TB uses a combination of TB drugs (antibiotics) which are harmful (toxic) to patients.
Published Studies Related to Trecator (Ethionamide)
A clinical trial of ethionamide and prothionamide for treatment of lepromatous leprosy. [2006.03]
In 1982-1984 we conducted a six-month clinical trial in 50 previously untreated lepromatous leprosy patients randomly assigned to directly observed monotherapy with one of two thioamides, ethionamide or prothionamide, each given six times a week at doses of either 250 mg or 500 mg... leprae in this study was found to be similar to that obtained previously with dapsone and clofazimine, but less than was obtained with rifampin, minocycline, clarithromycin, pefloxacin, and ofloxacin.
Pharmacokinetics of ethionamide administered under fasting conditions or with orange juice, food, or antacids. [2001.03]
This study was conducted in order to (i) determine the effect of food, orange juice, or antacids on the absorption of a single oral 500-mg dose of ethionamide (ETA) in healthy volunteers, including an assessment of bioequivalence, and (ii) determine ETA population pharmacokinetic (PK) parameters...
Pharmacokinetic evaluation of ethionamide suppositories. 
The absorption and elimination of ethionamide (ETA) after oral tablets and rectal suppositories were determined in 12 healthy, adult male volunteers. A randomized, double-blind, double-dummy, crossover design was used... Higher doses of ETA and serum concentration monitoring are recommended whenever the suppositories are used.
Pharmacokinetics and tissue distribution studies of orally administered nanoparticles encapsulated ethionamide used as potential drug delivery system in management of multi-drug resistant tuberculosis. [2011.01]
Sustained release nanoformulations of second line anti-tubercular drugs can help in reducing their dosing frequency and improve patient's compliance in multi-drug resistant tuberculosis (MDR TB). The objective of the current study was to investigate the pharmacokinetics and tissues distribution of ethionamide encapsulated in poly (DL-lactide-co-glycolide) (PLGA) nanoparticles...
Ethionamide cross- and co-resistance in children with isoniazid-resistant tuberculosis. [2009.11]
BACKGROUND: Ethionamide (ETH) is a structural analogue of isoniazid (INH). Both are pro-drugs requiring activation by separate and common enzyme pathways, which could lead to co- and/or cross-resistance. OBJECTIVE: To characterise paediatric INH-resistant mycobacterial isolates to investigate the presence of ETH resistance and mutations in the katG gene and the inhA promoter region... CONCLUSION: We found a high level of cross- and co-resistance with ETH among INH-resistant M. tuberculosis isolates from children in this geographic area.
Clinical Trials Related to Trecator (Ethionamide)
A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients. [Completed]
To determine the demographic, behavioral, clinical, and geographic risk factors associated
with the occurrence of multidrug-resistant pulmonary tuberculosis (MDRTB). To evaluate the
clinical and microbiological responses and overall survival of MDRTB patients who are treated
with levofloxacin-containing multiple-drug regimens chosen from a hierarchical list. Per
9/28/94 amendment, to assess whether persistent or recurrent positive sputum cultures of
patients who show failure or relapse are due to the same strain or reinfection with a new
Among TB patients, there has been an increase in progressive disease due to the emergence of
antimycobacterial drug-resistant strains of Mycobacterium tuberculosis. Failure to identify
patients at high risk for MDRTB increases the hazard for both treatment failure and
development of resistance to additional therapeutic agents. Efforts to improve survival in
patients with MDRTB will depend on improved methods of assessing the risk of acquisition of
MDRTB and identifying drug susceptibility patterns in a timely fashion.